Shubham Pant, MD on New Findings on Adagrasib in Advanced Solid Tumors, Including Biliary Tract Cancer

Posted: Wednesday, July 5, 2023

Shubham Pant, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the KRYSTAL-1 trial on adagrasib, a KRAS G12C inhibitor. The agent showed clinical activity across a broad range of tumor types and was well tolerated in patients with unresectable or metastatic solid tumors harboring a KRAS G12C mutation, including biliary tract cancer.

---